Vyteris, Inc. (VYTR.OB) Signs Agreement with Zealand Pharma on Active Transdermal Patch for Peptide Drugs
Vyteris, Inc., developer of the first FDA-approved active transdermal drug delivery system and a leader in active transdermal drug delivery technology, announced today that it has entered into an agreement with Zealand Pharma A/S, a Denmark-based biopharmaceutical company focused on discovering and developing innovative peptide-based drugs, to apply its technology to the controlled transdermal delivery of Zealand Pharma's peptide optimization technology. "This strategic partnership with Zealand Pharma, a recognized leader in peptide drug development, marks another milestone in the active roll-out of our patented smart patch transdermal technology for the delivery of high-value, therapeutic peptides," commented Dr. Haro Hartounian, president…